Literature DB >> 26903543

Combination of Levo-Tetrahydropalmatine and Low Dose Naltrexone: A Promising Treatment for Prevention of Cocaine Relapse.

Sarah Sushchyk1, Zheng-Xiong Xi1, Jia Bei Wang2.   

Abstract

Relapse to drug use is often cited as the major obstacle in overcoming a drug addiction. Whereas relapse can occur for a myriad of reasons, it is well established that complex neuroadaptations that occur over the course of addiction are major factors. Cocaine, as a potent dopamine transporter blocker, specifically induces alterations in the dopaminergic as well as other monoaminergic neurotransmissions, which lead to cocaine abuse and dependence. Evidence also suggests that adaptations in the endogenous opioids play important roles in pathophysiology of cocaine addiction. Following this evidence, we investigated a combination medication, levo-tetrahydropalmatine (l-THP) and low dose naltrexone (LDN), targeting primarily dopaminergic and endogenous opioid systems as a cocaine-relapse-prevention treatment. In the present study Wistar rats were used to assess the effects ofl-THP and LDN on cocaine self-administration, drug-seeking behavior during cocaine reinstatement, spontaneous locomotion, and effects on the endogenous opioid system. We determined that the combination ofl-THP and LDN reduces drug-seeking behavior during reinstatement more potently thanl-THP alone. Additionally, the combination ofl-THP and LDN attenuates the sedative locomotor effect induced byl-THP. Furthermore, we revealed that treatment with the combination ofl-THP and LDN has an upregulatory effect on both plasmaβ-endorphin and hypothalamic POMC that was not observed inl-THP-treated groups. These results suggest that the combination ofl-THP and LDN has great potential as an effective and well-tolerated medication for cocaine relapse prevention. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26903543      PMCID: PMC4851325          DOI: 10.1124/jpet.115.229542

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  54 in total

1.  Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine.

Authors:  M F Olive; H N Koenig; M A Nannini; C W Hodge
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

Review 2.  The validity of the reinstatement model of craving and relapse to drug use.

Authors:  Jonathan L Katz; Stephen T Higgins
Journal:  Psychopharmacology (Berl)       Date:  2003-04-15       Impact factor: 4.530

Review 3.  Novel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies.

Authors:  Chris P Bailey; Stephen M Husbands
Journal:  Expert Opin Drug Discov       Date:  2014-09-25       Impact factor: 6.098

4.  Naltrexone and relapse prevention treatment for cocaine-dependent patients.

Authors:  J M Schmitz; A L Stotts; H M Rhoades; J Grabowski
Journal:  Addict Behav       Date:  2001 Mar-Apr       Impact factor: 3.913

Review 5.  Cocaine dependence: a disease of the brain's reward centers.

Authors:  C A Dackis; C P O'Brien
Journal:  J Subst Abuse Treat       Date:  2001-10

6.  Individual differences in gene expression of vasopressin, D2 receptor, POMC and orexin: vulnerability to relapse to heroin-seeking in rats.

Authors:  Yan Zhou; Francesco Leri; Erin Cummins; Mary Jeanne Kreek
Journal:  Physiol Behav       Date:  2014-11-09

Review 7.  Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development.

Authors:  Donna M Platt; James K Rowlett; Roger D Spealman
Journal:  Psychopharmacology (Berl)       Date:  2002-07-17       Impact factor: 4.530

8.  Effect of experimenter-delivered and self-administered cocaine on extracellular beta-endorphin levels in the nucleus accumbens.

Authors:  I Roth-Deri; A Zangen; M Aleli; R G Goelman; G Pelled; R Nakash; I Gispan-Herman; T Green; Y Shaham; G Yadid
Journal:  J Neurochem       Date:  2003-03       Impact factor: 5.372

9.  Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans.

Authors:  M Haney; A S Ward; R W Foltin; M W Fischman
Journal:  Psychopharmacology (Berl)       Date:  2001-06       Impact factor: 4.530

10.  Is withdrawal-induced anxiety in alcoholism based on beta-endorphin deficiency?

Authors:  Falk Kiefer; Mirko Horntrich; Holger Jahn; Klaus Wiedemann
Journal:  Psychopharmacology (Berl)       Date:  2002-06-25       Impact factor: 4.530

View more
  7 in total

Review 1.  Involvement of Activated Brain Stress Responsive Systems in Excessive and "Relapse" Alcohol Drinking in Rodent Models: Implications for Therapeutics.

Authors:  Yan Zhou; Mary Jeanne Kreek
Journal:  J Pharmacol Exp Ther       Date:  2018-04-18       Impact factor: 4.030

Review 2.  Role of natural products in mitigation of toxic effects of methamphetamine: A review of in vitro and in vivo studies.

Authors:  Mohammad Moshiri; Ali Roohbakhsh; Mahdi Talebi; Milad Iranshahy; Leila Etemad
Journal:  Avicenna J Phytomed       Date:  2020 Jul-Aug

3.  Synthesis and evaluation of C9 alkoxy analogues of (-)-stepholidine as dopamine receptor ligands.

Authors:  Sudharshan Madapa; Satishkumar Gadhiya; Thomas Kurtzman; Ian L Alberts; Steven Ramsey; Maarten Reith; Wayne W Harding
Journal:  Eur J Med Chem       Date:  2016-09-14       Impact factor: 6.514

4.  Neural bases for attenuation of morphine withdrawal by Heantos-4: role of l-tetrahydropalmatine.

Authors:  Soyon Ahn; Maya O Nesbit; Haiyan Zou; Giada Vacca; Peter Axerio-Cilies; Tran Van Sung; Anthony G Phillips
Journal:  Sci Rep       Date:  2020-12-04       Impact factor: 4.379

Review 5.  A Comprehensive Review on the Chemical Properties, Plant Sources, Pharmacological Activities, Pharmacokinetic and Toxicological Characteristics of Tetrahydropalmatine.

Authors:  Qinyun Du; Xianli Meng; Shaohui Wang
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

Review 6.  Enkephalin as a Pivotal Player in Neuroadaptations Related to Psychostimulant Addiction.

Authors:  Bethania Mongi-Bragato; María P Avalos; Andrea S Guzmán; Flavia A Bollati; Liliana M Cancela
Journal:  Front Psychiatry       Date:  2018-05-28       Impact factor: 4.157

7.  Transgenic increase in the β-endorphin concentration in cerebrospinal fluid alleviates morphine-primed relapse behavior through the μ opioid receptor in rats.

Authors:  Yan He; Yugang Lu; Yang Shen; Feixiang Wu; Xuewu Xu; Erliang Kong; Zhangxiang Huang; Yuming Sun; Weifeng Yu
Journal:  J Med Virol       Date:  2019-02-19       Impact factor: 2.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.